This site is intended for healthcare professionals

Keytruda monotherapy is EU approved for adult and pediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma.- Merck Inc.

Read time: 1 mins
Last updated:28th Jun 2021
Published:19th Mar 2021
Condition: Hodgkin Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest